Article
The functional mu opioid receptor (OPRM1) Asn40Asp variant predicts short-term response to nicotine replacement therapy in a clinical trial.
The pharmacogenomics journal - 1 Jan 2004
Lerman C, Wileyto E P, Patterson F, Rukstalis M, Audrain-McGovern J, Restine S, Shields P G, Kaufmann V, Redden D, Benowitz N, Berrettini W H
Abstract excerpt
To determine whether the functional mu-opioid receptor (OPRM1) Asn40Asp variant predicts the comparative efficacy of different forms of NRT, we conducted a clinical trial of transdermal nicotine (TN) vs nicotine nasal spray (NS) in 320 smokers of European ancestry. Smokers carrying the OPRM1 Asp40 variant (n=82) were significantly more likely than those homozygous for the Asn40 variant (n=238) to be abstinent at...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.